Does the media prefer TSHA or HHH?

In the previous week, Taysha Gene Therapies and Taysha Gene Therapies both had 4 articles in the media. Taysha Gene Therapies' average media sentiment score of 0.94 beat Howard Hughes' score of 0.67 indicating that Taysha Gene Therapies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Taysha Gene Therapies 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Howard Hughes 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to CGON or TSHA?

In the previous week, CG Oncology had 3 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 7 mentions for CG Oncology and 4 mentions for Taysha Gene Therapies. Taysha Gene Therapies' average media sentiment score of 0.94 beat CG Oncology's score of 0.82 indicating that Taysha Gene Therapies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Taysha Gene Therapies 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TSHA or MIRM?

In the previous week, Mirum Pharmaceuticals had 4 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 8 mentions for Mirum Pharmaceuticals and 4 mentions for Taysha Gene Therapies. Taysha Gene Therapies' average media sentiment score of 0.94 beat Mirum Pharmaceuticals' score of 0.62 indicating that Taysha Gene Therapies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Taysha Gene Therapies 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TSHA or TVTX?

In the previous week, Travere Therapeutics had 34 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 38 mentions for Travere Therapeutics and 4 mentions for Taysha Gene Therapies. Taysha Gene Therapies' average media sentiment score of 0.94 beat Travere Therapeutics' score of 0.25 indicating that Taysha Gene Therapies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Taysha Gene Therapies 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Travere Therapeutics 17 Very Positive mention(s) 7 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is TSHA or ORKA more profitable?

Oruka Therapeutics' return on equity of -21.65% beat Taysha Gene Therapies' return on equity. Company Net Margins Return on Equity Return on Assets Taysha Gene Therapies N/A -56.19% -41.84% Oruka Therapeutics N/A -21.65% -20.88%

Does the media prefer TSHA or ORKA?

In the previous week, Oruka Therapeutics had 11 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 15 mentions for Oruka Therapeutics and 4 mentions for Taysha Gene Therapies. Taysha Gene Therapies' average media sentiment score of 0.94 beat Oruka Therapeutics' score of 0.26 indicating that Taysha Gene Therapies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Taysha Gene Therapies 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oruka Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Taysha Gene Therapies (TSHA) Competitors

$5.02 -0.14 (-2.71%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$5.02 0.00 (0.00%)

As of 09/18/2026 07:30 PM Eastern

Compare

TSHA vs. HHH, CGON, MIRM, TVTX, and ORKA

Should you buy Taysha Gene Therapies stock or one of its competitors? Taysha Gene Therapies's main competitors and comparable companies include Howard Hughes (HHH), CG Oncology (CGON), Mirum Pharmaceuticals (MIRM), Travere Therapeutics (TVTX), and Oruka Therapeutics (ORKA). Companies are selected based on similarities in market, industry, and size.

How does Taysha Gene Therapies compare to Howard Hughes?

Taysha Gene Therapies (NASDAQ:TSHA) and Howard Hughes (NYSE:HHH) are related companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.

Taysha Gene Therapies has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market. Comparatively, Howard Hughes has a beta of 1.14, suggesting that its stock price is 14% more volatile than the broader market.

In the previous week, Taysha Gene Therapies and Taysha Gene Therapies both had 4 articles in the media. Taysha Gene Therapies' average media sentiment score of 0.94 beat Howard Hughes' score of 0.67 indicating that Taysha Gene Therapies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Taysha Gene Therapies	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Howard Hughes	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Howard Hughes has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Howard Hughes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Taysha Gene Therapies	$9.77M	167.42	-$109M	-$0.42	N/A
Howard Hughes	$1.47B	2.44	$123.90M	$4.94	12.19

Taysha Gene Therapies currently has a consensus target price of $12.77, suggesting a potential upside of 154.37%. Howard Hughes has a consensus target price of $79.00, suggesting a potential upside of 31.22%. Given Taysha Gene Therapies' stronger consensus rating and higher possible upside, analysts clearly believe Taysha Gene Therapies is more favorable than Howard Hughes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00
Howard Hughes	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

77.7% of Taysha Gene Therapies shares are held by institutional investors. Comparatively, 93.8% of Howard Hughes shares are held by institutional investors. 3.5% of Taysha Gene Therapies shares are held by company insiders. Comparatively, 47.7% of Howard Hughes shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Howard Hughes has a net margin of 12.31% compared to Taysha Gene Therapies' net margin of 0.00%. Howard Hughes' return on equity of 7.51% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	N/A	-56.19%	-41.84%
Howard Hughes	12.31%	7.51%	2.41%

Summary

Howard Hughes beats Taysha Gene Therapies on 9 of the 16 factors compared between the two stocks.

How does Taysha Gene Therapies compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and Taysha Gene Therapies (NASDAQ:TSHA) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

CG Oncology has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market. Comparatively, Taysha Gene Therapies has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market.

In the previous week, CG Oncology had 3 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 7 mentions for CG Oncology and 4 mentions for Taysha Gene Therapies. Taysha Gene Therapies' average media sentiment score of 0.94 beat CG Oncology's score of 0.82 indicating that Taysha Gene Therapies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Taysha Gene Therapies	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CG Oncology currently has a consensus price target of $87.78, indicating a potential upside of 17.63%. Taysha Gene Therapies has a consensus price target of $12.77, indicating a potential upside of 154.37%. Given Taysha Gene Therapies' stronger consensus rating and higher possible upside, analysts plainly believe Taysha Gene Therapies is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

26.6% of CG Oncology shares are held by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are held by institutional investors. 4.8% of CG Oncology shares are held by company insiders. Comparatively, 3.5% of Taysha Gene Therapies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Taysha Gene Therapies has a net margin of 0.00% compared to CG Oncology's net margin of -3,602.68%. CG Oncology's return on equity of -25.20% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	-3,602.68%	-25.20%	-23.98%
Taysha Gene Therapies	N/A	-56.19%	-41.84%

Taysha Gene Therapies has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,637.21	-$160.99M	-$2.69	N/A
Taysha Gene Therapies	$9.77M	167.42	-$109M	-$0.42	N/A

Summary

Taysha Gene Therapies beats CG Oncology on 12 of the 17 factors compared between the two stocks.

How does Taysha Gene Therapies compare to Mirum Pharmaceuticals?

Taysha Gene Therapies (NASDAQ:TSHA) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

Taysha Gene Therapies has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market.

77.7% of Taysha Gene Therapies shares are owned by institutional investors. 3.5% of Taysha Gene Therapies shares are owned by company insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Taysha Gene Therapies has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -139.18%. Mirum Pharmaceuticals' return on equity of -36.28% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	N/A	-56.19%	-41.84%
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%

Mirum Pharmaceuticals has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Taysha Gene Therapies	$9.77M	167.42	-$109M	-$0.42	N/A
Mirum Pharmaceuticals	$521.31M	11.44	-$23.36M	-$14.55	N/A

Taysha Gene Therapies currently has a consensus target price of $12.77, indicating a potential upside of 154.37%. Mirum Pharmaceuticals has a consensus target price of $137.31, indicating a potential upside of 49.53%. Given Taysha Gene Therapies' stronger consensus rating and higher probable upside, analysts plainly believe Taysha Gene Therapies is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

In the previous week, Mirum Pharmaceuticals had 4 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 8 mentions for Mirum Pharmaceuticals and 4 mentions for Taysha Gene Therapies. Taysha Gene Therapies' average media sentiment score of 0.94 beat Mirum Pharmaceuticals' score of 0.62 indicating that Taysha Gene Therapies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Taysha Gene Therapies	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Taysha Gene Therapies beats Mirum Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Taysha Gene Therapies compare to Travere Therapeutics?

Taysha Gene Therapies (NASDAQ:TSHA) and Travere Therapeutics (NASDAQ:TVTX) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, risk, institutional ownership and valuation.

Taysha Gene Therapies has a beta of 1.19, indicating that its share price is 19% more volatile than the broader market. Comparatively, Travere Therapeutics has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market.

77.7% of Taysha Gene Therapies shares are held by institutional investors. 3.5% of Taysha Gene Therapies shares are held by insiders. Comparatively, 4.4% of Travere Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Taysha Gene Therapies has a net margin of 0.00% compared to Travere Therapeutics' net margin of -7.35%. Travere Therapeutics' return on equity of -55.15% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	N/A	-56.19%	-41.84%
Travere Therapeutics	-7.35%	-55.15%	-6.88%

Travere Therapeutics has higher revenue and earnings than Taysha Gene Therapies. Travere Therapeutics is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Taysha Gene Therapies	$9.77M	167.42	-$109M	-$0.42	N/A
Travere Therapeutics	$490.73M	12.06	-$25.55M	-$0.46	N/A

In the previous week, Travere Therapeutics had 34 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 38 mentions for Travere Therapeutics and 4 mentions for Taysha Gene Therapies. Taysha Gene Therapies' average media sentiment score of 0.94 beat Travere Therapeutics' score of 0.25 indicating that Taysha Gene Therapies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Taysha Gene Therapies	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Travere Therapeutics	17 Very Positive mention(s)	7 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Taysha Gene Therapies currently has a consensus price target of $12.77, indicating a potential upside of 154.37%. Travere Therapeutics has a consensus price target of $68.00, indicating a potential upside of 8.35%. Given Taysha Gene Therapies' stronger consensus rating and higher possible upside, analysts plainly believe Taysha Gene Therapies is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00
Travere Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Taysha Gene Therapies beats Travere Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Taysha Gene Therapies compare to Oruka Therapeutics?

Taysha Gene Therapies (NASDAQ:TSHA) and Oruka Therapeutics (NASDAQ:ORKA) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

In the previous week, Oruka Therapeutics had 11 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 15 mentions for Oruka Therapeutics and 4 mentions for Taysha Gene Therapies. Taysha Gene Therapies' average media sentiment score of 0.94 beat Oruka Therapeutics' score of 0.26 indicating that Taysha Gene Therapies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Taysha Gene Therapies	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oruka Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Taysha Gene Therapies has a beta of 1.19, meaning that its share price is 19% more volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.34, meaning that its share price is 134% less volatile than the broader market.

Oruka Therapeutics' return on equity of -21.65% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	N/A	-56.19%	-41.84%
Oruka Therapeutics	N/A	-21.65%	-20.88%

Oruka Therapeutics has lower revenue, but higher earnings than Taysha Gene Therapies. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Taysha Gene Therapies	$9.77M	167.42	-$109M	-$0.42	N/A
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A

77.7% of Taysha Gene Therapies shares are owned by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are owned by institutional investors. 3.5% of Taysha Gene Therapies shares are owned by company insiders. Comparatively, 23.5% of Oruka Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Taysha Gene Therapies currently has a consensus target price of $12.77, indicating a potential upside of 154.37%. Oruka Therapeutics has a consensus target price of $133.00, indicating a potential upside of 40.06%. Given Taysha Gene Therapies' stronger consensus rating and higher possible upside, equities research analysts clearly believe Taysha Gene Therapies is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Summary

Taysha Gene Therapies beats Oruka Therapeutics on 10 of the 15 factors compared between the two stocks.

Get Taysha Gene Therapies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TSHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TSHA vs. The Competition

Export

Metric	Taysha Gene Therapies	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.68B	$3.91B	$7.25B	$13.13B
Dividend Yield	N/A	3.65%	2.57%	12.94%
P/E Ratio	-11.95	14.08	273.81	25.39
Price / Sales	167.42	1,407.75	692.78	109.00
Price / Cash	N/A	110.75	77.42	51.66
Price / Book	5.58	15.45	10.45	6.33
Net Income	-$109M	-$22.78M	$3.48B	$358.24M
7 Day Performance	N/A	-1.22%	0.88%	1.17%
1 Month Performance	-21.93%	-4.44%	-1.59%	-2.59%
1 Year Performance	77.39%	37.78%	18.08%	5.97%

Taysha Gene Therapies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TSHA Taysha Gene Therapies	3.3669 of 5 stars	$5.02 -2.7%	$12.77 +154.4%	+67.9%	$1.68B	$9.77M	N/A	99	News Coverage Analyst Forecast High Trading Volume
HHH Howard Hughes	4.014 of 5 stars	$60.97 -0.9%	$79.00 +29.6%	-28.0%	$3.68B	$1.47B	12.34	500
CGON CG Oncology	2.8671 of 5 stars	$73.79 +2.0%	$87.78 +19.0%	+92.2%	$6.41B	$6.23M	N/A	142
MIRM Mirum Pharmaceuticals	3.0598 of 5 stars	$96.75 -1.5%	$137.31 +41.9%	+21.9%	$6.38B	$618.07M	N/A	433
TVTX Travere Therapeutics	1.6019 of 5 stars	$65.79 -0.6%	$68.00 +3.4%	+159.4%	$6.24B	$591.33M	N/A	497	Trending News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TSHA) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Taysha Gene Therapies (TSHA) Competitors

TSHA vs. HHH, CGON, MIRM, TVTX, and ORKA

How does Taysha Gene Therapies compare to Howard Hughes?

Summary

How does Taysha Gene Therapies compare to CG Oncology?

Summary

How does Taysha Gene Therapies compare to Mirum Pharmaceuticals?

Summary

How does Taysha Gene Therapies compare to Travere Therapeutics?

Summary

How does Taysha Gene Therapies compare to Oruka Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TSHA vs. The Competition

Taysha Gene Therapies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Taysha Gene Therapies (TSHA) Competitors

TSHA vs. HHH, CGON, MIRM, TVTX, and ORKA

How does Taysha Gene Therapies compare to Howard Hughes?

Which has more volatility & risk, TSHA or HHH?

Does the media prefer TSHA or HHH?

Which has stronger valuation & earnings, TSHA or HHH?

Do analysts prefer TSHA or HHH?

Do insiders & institutionals hold more shares of TSHA or HHH?

Is TSHA or HHH more profitable?

Summary

How does Taysha Gene Therapies compare to CG Oncology?

Which has more risk and volatility, CGON or TSHA?

Does the media refer more to CGON or TSHA?

Do analysts prefer CGON or TSHA?

Do insiders and institutionals have more ownership in CGON or TSHA?

Is CGON or TSHA more profitable?

Which has preferable earnings and valuation, CGON or TSHA?

Summary

How does Taysha Gene Therapies compare to Mirum Pharmaceuticals?

Which has more volatility & risk, TSHA or MIRM?

Do institutionals & insiders have more ownership in TSHA or MIRM?

Is TSHA or MIRM more profitable?

Which has better valuation & earnings, TSHA or MIRM?

Do analysts recommend TSHA or MIRM?

Does the media prefer TSHA or MIRM?

Summary

How does Taysha Gene Therapies compare to Travere Therapeutics?

Which has more volatility & risk, TSHA or TVTX?

Do institutionals and insiders have more ownership in TSHA or TVTX?

Is TSHA or TVTX more profitable?

Which has better earnings & valuation, TSHA or TVTX?

Does the media refer more to TSHA or TVTX?

Do analysts prefer TSHA or TVTX?

Summary

How does Taysha Gene Therapies compare to Oruka Therapeutics?

Does the media prefer TSHA or ORKA?

Which has more risk & volatility, TSHA or ORKA?

Is TSHA or ORKA more profitable?

Which has preferable earnings & valuation, TSHA or ORKA?

Do institutionals & insiders have more ownership in TSHA or ORKA?

Do analysts recommend TSHA or ORKA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TSHA vs. The Competition

Taysha Gene Therapies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools